Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Status:
Completed
Trial end date:
2021-07-24
Target enrollment:
Participant gender:
Summary
The overall objective of this protocol is to improve the cure rate of relapsed precursor
B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma.
This phase II trial is studying risk-directed therapy for B-lymphoblastic leukemia or
lymphoma in first relapse. Standard risk (SR) and high risk (HR) participants will receive
different therapy. Treatment will consist of chemotherapy for SR participants, and
chemotherapy followed by hematopoietic stem cell transplant (HSCT) for HR in first relapse.
Induction therapy consists of three blocks of chemotherapy. The first block is a novel
immunotherapy regimen that includes chemotherapy, rituximab and infusion of haploidentical
natural killer (NK) cells. SR participants will continue to receive chemotherapy for a total
duration of approximately 2 years. HR participants will be candidates for HSCT and will
proceed to transplant once a suitable donor is found and their minimal residual disease (MRD)
is negative.